Clayton Russell 4
4 · Larimar Therapeutics, Inc. · Filed Jan 19, 2024
Insider Transaction Report
Form 4
Clayton Russell
Chief Medical Officer
Transactions
- Award
Common Stock
2024-01-17+22,500→ 22,500 total - Award
Stock Option (Right to Buy)
2024-01-17+135,000→ 135,000 totalExercise: $4.21Exp: 2034-01-17→ Common Stock (135,000 underlying)
Footnotes (2)
- [F1]Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F2]The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.